Drug Pricing Based on Patient Outcomes

According to this post in FierceHealthcare pharma companies have started adjusting pricing on their drugs to reflect its performance on improving patient outcomes. Merck has agreed to adjust pricing on Januvia and Janumet, which are diabetes drugs, based on how well they treat type 2 diabetes.

Performance-based pricing for meds is extremely rare, but with increased pressure coming from insurance companies it is only a matter of time before we will see more and more pharma companies following this pattern.

Read more about this piece on the NY Times